Story perspectives

MIT Develops Implantable Device for Long-Lasting Insulin Production

3/27/2026

Summary

Story summary

Massachusetts Institute of Technology (MIT) researchers are developing an implantable device with insulin-producing cells that resist immune rejection.
In mice, the device maintained cell health with an oxygen generator and supported insulin production for at least 90 days.
A team at Kumamoto University created a cyclic peptide that enables oral insulin delivery, with pharmacological bioavailability of 33–41%.
Both innovations aim to reduce injections, with future studies extending longevity and effectiveness.

1 of 1

Story summary

Massachusetts Institute of Technology (MIT) researchers are developing an implantable device with insulin-producing cells that resist immune rejection.
In mice, the device maintained cell health with an oxygen generator and supported insulin production for at least 90 days.
A team at Kumamoto University created a cyclic peptide that enables oral insulin delivery, with pharmacological bioavailability of 33–41%.
Both innovations aim to reduce injections, with future studies extending longevity and effectiveness.